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Background
The landmark US Multimodal Treatment of ADHD (MTA) study
established the benefits of individualised medication titration
and optimisation strategies to improve short- to medium-term
outcomes in attention-deficit hyperactivity disorder (ADHD).
This individualised medication management approach was
subsequently incorporated into the National Institute for Health
and Care Excellence (NICE) ADHD Clinical Guidelines (NICE
CG78). However, little is known about clinicians’ attitudes
towards implementing these medication management
strategies for ADHD in routine care.
Aims
To examine National Health Service (NHS) healthcare
professionals’ consensus on ADHD medication management
strategies.
Method
Using the Delphi method, we examined perceptions on the
importance and feasibility of implementing 103 ADHD
treatment statements from sources including the UK
NICE ADHD guidelines and US medication management
algorithms.
Results
Certain recommendations for ADHD medication management
were judged as important and feasible to implement, including
a stepwise titration of stimulant medication. Other
recommendations were perceived as important but not
feasible to implement in routine practice, such as weekly clinic
follow-up with the family during titration and collection of
follow-up symptom questionnaires.
Conclusions
Many of the key guideline recommendations for ADHD
medication management are viewed by clinicians as important
and feasible to implement. However, some recommendations
present significant implementation challenges within the
context of routine NHS clinical care in England.
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Attention-deficit hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder, which left untreated can have a
significant impact on the lives of affected young people, their
families and society.1,2 In the UK, the National Institute for Health
and Care Excellence (NICE) ADHD guidelines3 provide the gold
standard for the diagnosis and management of ADHD, advocating
medication as the first-line treatment for severe or moderate
ADHD. The landmark US Multimodal Treatment of ADHD
(MTA) study4 investigated the clinical effectiveness of a medica-
tion management strategy which involved a carefully monitored
individualised titration period. This protocol resulted in signifi-
cantly improved ADHD outcomes in the short to medium term.5,6
The Texas Children’s Medication Algorithm Project7,8 was
developed as a clinical tool to implement the MTA’s medication
protocol into routine clinical practice. Their findings indicated
some deviance from the schedule, with a reluctance to titrate
upwards and problems obtaining regular ratings from teachers
and parents.8 These findings indicate that despite the MTA
medication protocol being considered by many as the US ‘gold
standard’ in medication management, the Texas project found
that some items were not feasible to implement in routine clinical
practice. However, given cross-country differences in clinical
practice, including differences in the delivery of ‘community
care’ for ADHD and healthcare systems between the USA and
UK, these findings may not translate to UK practice. Furthermore,
since the MTA study which was conducted in the 1990s,
prescribing practices have changed, with the introduction of
long-acting ADHD medication.
In the UK, there is evidence of variable implementation of
NICE clinical guidelines in ‘real-world’ settings9 and the specific
implementation challenges of the NICE ADHD guideline have
been highlighted.10 More recently, audit data collected within the
East Midlands region of the UK have demonstrated poor
adherence to NICE guidelines, particularly with regard to
measuring blood pressure/heart rate, formal recording of side-
effects and the use of rating scales to aid assessment and
management.11 These findings indicate a gap between best
practice guidelines and implementation of recommendations in
‘real-world’ practice that needs to be understood and addressed.
Given the difficulties in implementing the Texas Algorithm (based
on the MTA protocol) in the USA, variable implementation of
NICE guidelines in general in the UK and the evidence of poor
adherence to aspects of the NICE ADHD guideline, we decided to
investigate how the MTA study-based practice parameters and
NICE guideline recommendations are perceived by National
Health Service (NHS) clinicians with respect to both importance
and feasibly for implementation.
We adopted a multi-method approach to determine UK
stakeholder (parent/carer and NHS healthcare professional)*Joint first authors.
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perceptions of current and best practice clinical guideline
recommendations for assessment and medical management of
ADHD. Data were collected via an online survey, a parent/carer
focus group and a healthcare professional’s workshop. These
findings were used to generate a set of statements on ADHD
medication management which were then rated for importance
and feasibility using a Delphi survey method.
Method
Delphi survey development
The items for the Delphi survey were developed through four
different methodological approaches. Initially a scoping literature
review was conducted. Eight healthcare databases were searched
(Allied and Complementary Medicine Database (AMED), British
Nursing Index, Embase, HMIC (Health Management Information
Consortium), MEDLINE, PsycINFO, CINAHL and Health Busi-
ness Elite) for papers published in English, using the keywords
ADHD and medication prescribing/monitoring/guidelines/titra-
tion. Informal searching, including hand-searching of article
references and web search engines (including Google and Google
Scholar) was also undertaken. In addition, colleagues who have
contact with patients with ADHD were also consulted with regard
to further literature that might be available. On the basis of this
literature search, NICE guidelines were shown as the most
prominent and ‘gold-standard’ approach to inform medication
monitoring of ADHD in the UK. The MTA and Texas Algorithm
were shown to be one of the most cited and influential sources for
ADHD practice parameters in the USA. Many of the MTA
principles are incorporated within the NICE guideline recommen-
dations. However, the Texas Algorithm provides more specific
details on aspects of titration and optimisation than do NICE
guideline recommendations and hence we include statements
from both sources. The findings from the literature search were
used to inform questions for an online survey aimed at establish-
ing healthcare professionals’ perceptions of medication prescrib-
ing and monitoring.
Online survey
Eighty-five healthcare professionals responsible for the treatment of
children and young people with ADHD across four participating
NHS trusts (health provider organisations) within the regional
Collaboration for Leadership in Applied Health Research and Care
(CLAHRC) footprint were invited to participate in the online
survey. Consent to participate was implied by survey participation.
Responses were obtained from 26 healthcare professionals
(response rate 31%), 12 of whom were community paediatricians
(46%) and 14 child and adolescent psychiatrists (54%) working in
NHS trusts across three English counties (Nottinghamshire (n=12),
Derbyshire (n=9) and Lincolnshire (n=5)). One respondent was
excluded from analysis because of low question completion within
the survey (1% completion), resulting in a sample of 25 healthcare
professionals. Although this response rate was relatively low, it is
similar to that found in other online surveys aimed at healthcare
professionals working in ADHD.12
The survey investigated healthcare professionals’ current
practice in diagnosis, initiation of medication, titration, assess-
ment of response to medication and maintenance, which were
based on strategies derived from NICE guidelines, the MTA group
and the Texas Children’s Medication Algorithm Project.
The online survey questions and semi-structured focus groups
were devised by drawing on the current literature and consultation
within the study group, which included three consultant psychiatrists,
one child and adolescent mental health nurse and two researchers
with expertise in qualitative methods. Each member reviewed the
questions to ascertain their appropriateness to the research question.
Parent/carer focus group
To assess parents/caregivers’ perceptions of medication manage-
ment for children with ADHD, nine parents/carers of children
currently receiving medication for ADHD attended a focus group,
having read an information sheet and provided written consent
prior to their participation.
The focus group was semi-structured and consisted of 12
questions pertaining to the families’ experiences of starting medi‐
cation, how and when they were monitored, how information was
fed back to them, the effect of the medication and their perceptions
of the utility and feasibility of changes to medication management.
Audio recordings from the focus group were anonymised, tran-
scribed verbatim and thematically analysed in accordance with the
guidelines of Braun & Clarke.13 Themes were derived inductively
and verified via interrater reliability measures. The researchers
utilised an essentiality/realist paradigm13 that sought to understand
medication management through the words of the participants, as
opposed to the researchers’ co-created meaning.
Healthcare professionals’ workshop
To further elucidate healthcare professionals’ views of medication, a
workshop was conducted with 22 healthcare professionals. The
sample comprised 11 consultant child and adolescent psychiatrists,
4 nurses/nurse specialists, 5 community paediatricians and 2 NHS
managers. Consent to participate was implied by attendance. From
this sample, five groups were created to discuss different issues
which concernedthe decision to medicate and choice of drug, titra‐
tion, medication maintenance, rating scales/outcomes, treatment
adherence and engagement with the aim of identifying current and
best practice. Verbal feedback from the healthcare professionals’
discussions were collated via written notes and summarised.
Delphi study
The Delphi method is an interactive method utilising an expert
panel answering questions in two or more rounds to achieve
consensus. Participants are given feedback on question responses
after each round; the process terminates once a predefined
stopping point is reached.14,15 In this study, the aim of the Delphi
process was to determine expert consensus on medication
management strategies. The combination of multiple methodolo-
gies used to inform the Delphi survey ensured that items were
comprehensive and relevant to aspects of medication management
identified as relevant by multiple stakeholders.
Expert panel
The expert panel comprised 12 healthcare professionals working
within the four participating NHS trusts: 7 child and adolescent
psychiatrists, 3 consultant community paediatricians and 2 ADHD
nurse prescribers, all experienced in the assessment and treatment
of ADHD. Consent to participate was implied by acceptance of the
invitation to form part of the expert group.
Procedure
Healthcare professionals were invited by email to become a
member of the expert group. Statements for the Delphi study
were drawn from the findings of the online survey, the parent/
carer focus group, the healthcare professional workshop, the NICE
guidelines,3 the MTA Cooperative Group4,16 and the Texas
Children’s Medication Algorithm Project.7,8 Some additional
statements were added by the study team to determine clinical
opinion on treatment choices or less directive recommendations.
For example, reasons to choose atomoxetine and titration doses
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should be increased as required up to British National Formulary
(BNF) limits (see Table 1 for statement source). The final Delphi
questionnaire comprised 103 statements, 92 of which were to be
rated on both their importance and feasibility. A subset of
statements (n=11) pertaining to clinician choice/preference and
where issues of feasibility were not applicable were rated on
importance alone. A 9-point Likert scale was used as a response
option for each statement, with scores 7–9 denoting the statement
is ‘important’ and/or ‘feasible’ and 1–3 denoting the statement is
‘unimportant’ and/or ‘unfeasible’.
The expert group completed round one of the questionnaire
online using www.surveymonkey.com and individualised ques-
tionnaires were emailed to panelists for round two. In the second
round, respondents were given the option to either retain their
original score or modify it in light of the group median score.
Similar to other studies, the survey was performed exclusively
online.17,18 In line with the guidance of Jones & Hunter,19 all
feedback was anonymous.
Data analysis methodology
Cut-off points for consensus drew on convention/standards adopted
by Morrison & Barratt15 and Langlands et al;20 how ever a broader
percentage gap was used to determine whether a statement should
be re-rated, to minimise the influence of a smaller number of
participants in this study. The following criteria were employed:
1. Items were considered to have metcrteria for consensus if
80% or more of the panel (10/12 members) rated the
statement as 7, 8 or 9 (important/feasible) or as 1, 2 or 3
(unimportant/unfeasible).
2. Items were re-presented in the second round if 50–79% of
the panel rated an item as 7–9 or 1–3.
3. Items were omitted from the second round if less than
50% of the panel rated an item as 7–9 or 1–3.
Round one resulted in 43 statements meeting criteria for con‐
sensus on importance and/or feasibility, four of which were rated
unimportant and/or unfeasible. Fifty-five statements were re-rated
on importance and/or feasibility during round two.
Ethical approval was granted by the local Research Ethics
Committee and Research and Development Departments of
Nottinghamshire Healthcare NHS Trust, Nottingham University
Hospitals NHS Trust, Lincolnshire Partnership NHS Foundation
Trust and Derbyshire Healthcare NHS Foundation Trust.
Results
Four different categories were used to cluster statements:
. Category 1: statements rated as important and feasible
. Category 2: statements rated as important but not feasible
. Category 3: statements rated as feasible but not important
. Category 4: statements rated as neither important nor
feasible
For the purpose of this paper, we only report on statements in
category 1 or 2 as these two categories allow an understanding of
what clinicians consider to be important in ADHD practice as well
as highlighting difficulties in implementing these aspects into
routine care. At the end of the Delphi study, 24 statements reached
consensus as being both ‘important’ (important/very important)
and ‘feasible’ (feasible/very feasible), supporting the inclusion
of these in ADHD medication management protocol (Table 1).
It should be noted that there are some instances where the final
median score for a statement was high, but criteria for consensus
(≥80 agreement) were not met. For example, a median score of 8,
whereby 9/12 panelists scored 7–9 (statement 60).
ADHD assessment
The Delphi study revealed a consensus on both the importance and
feasibility of assessing and describing impairment level alongside
the NICE recommendation to document comorbid conditions
(Table 1, statements 1 and 5). Whereas 80% (20/25) of survey
respondents agreed that it was important to distinguish between
the NICE ADHD guideline descriptions of moderate and severe
ADHD during assessment, only 12% (3/25) of respondents
thought that this was an easy distinction to make in practice. The
possible difficulty in assessing ADHD-related impairment may
potentially be exacerbated by its poor construct definition,21–23 the
need to assess impairment across multiple domains and dis‐
entangle impairment related to comorbid conditions, as well as
the weak association between symptom severity and severity of
impairment.22–24
Decision to medicate, drug choice and information
provision to parents
The Delphi study revealed support for the NICE guideline that
drug treatment should be offered to all children with severe
ADHD (Table 1, statement 6) and that methylphenidate should
normally be considered as the first line of drug treatment (Table 1,
statement 15). However, whereas clinicians supported the clinical
importance of the NICE guideline recommendation to offer
behavioural advice alongside drug treatment (Table 2, statement
7) or to offer behavioural therapy prior to medication in cases of
mild/moderate ADHD (Table 2, statement 9), there was no
consensus on the feasibility of this. This may reflect a lack of
resources within clinics; many NHS clinics are not commissioned
or resourced to provide behavioural management advice or
evidence-based parent programmes and so NHS healthcare
professionals need to recommend that parents seek out this
element of treatment from other agencies. This finding highlights
the difficulty the NHS may have in implementing NICE ADHD
guidance for access to behavioural interventions, suggesting that
the recommendations were perhaps more aspirational than a
reflection of what could currently be delivered in practice.
The importance and feasibility of discussing medication
benefits and adverse effects with families also obtained consensus
within the Delphi study (Table 1, statement 25) which was also
highlighted as important by parent/carers in the focus group.
Medication initiation and titration
A consensus was reached in the Delphi study on both the
importance and feasibility of NICE recommendations to document
physical parameters (blood pressure, heart rate, weight and height;
Table 1, statement 43) and cardiac risk factors before starting
medication (Table 1, statement 44), administering the lowest
available dose when prescribing methylphenidate and titrating up
to BNF limits (Table 1, statements 45 and 59). Documenting the
titration schedule at initiation, specifying drug, dose, duration of
each step and review date (Table 1, statement 56), and titrating with
regular stepwise dose increases (Table 1, statement 48) also met
consensus on importance and feasibility, suggesting acceptance of
more protocol-driven, MTA-style, titration schedules. Consensus
also emerged on the importance and feasibility of a maximum
duration of 12 weeks for titration, with 2–4 weeks between dose
increments (Table 1, statement 61), longer than the 4–6 weeks for
titration recommended by NICE. Support in our study for a longer
duration of titration may reflect clinician views on the challenges of
assessing improvement within 4–6 weeks in the multiple outcomes
recommended by NICE (symptom reduction, behaviour change,
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educational/relationship improvement) within a patient group
typified by the presence of comorbidities21 and where teacher/
parent feedback may conflict.25 Furthermore, healthcare profes-
sionals from the workshop reported difficulties with patients not
attending follow-up appointments regularly, thus potentially delay-
ing clinical decision-making.
Our findings suggested some conflict between the frequencies of
contact deemed most beneficial as opposed to that deemed most
Table 1 Category 1 Delphi statements (n=24) reaching consensus on both importance and feasibil ity
Delphi
statement
number Category 1 statements
Importance
median
score
Feasibility
median
score
Source:
NICE
Source:
MTA/
Texas
Source:
stakeholder
Source:
study
team
1 Baseline assessment of ADHD should include a description of
impairment (severe/mild-moderate).
9 8 ✓
5 Baseline assessment should routinely document comorbid
conditions
9 9 ✓
6 Drug treatment should be offered to all children with severe ADHD 9 8.5 ✓
43 A physical examination, including recording of pulse, blood
pressure, height and weight should occur before starting
medication
9 9 ✓
44 Cardiovascular risk factors should be asked about and
documented
9 9 ✓
45 The starting dose of methylphenidate should be the lowest
available dose of the prescribed formulation
8.5 9 ✓
49 Atomoxetine should be titrated on a ‘milligram per kilogram’ basis 7 7 ✓
50 The dose of atomoxetine should be increased 7 days after
initiation
7.5 9 ✓
62 Side-effects should be recorded at each dose change by
parents
8.5 9 ✓
86 Compliance with medication should be assessed by discussion
with the parent/carer and the child/young person
9 9 ✓
95 Height should be measured every 6 months 9 9 ✓
96 Weight should be measured 3 and 6 months after drug treatment
has started and every 6 months thereafter
9 9 ✓
97 Height and weight should be recorded on a growth chart 9 9 ✓
101 The continuing benefit of medication should be formally reviewed
and a decision documented on an annual basis with input from
the parent/carer, young person and school
9 9 ✓
14 Where drug treatment is considered appropriate, methylphenidate,
atomoxetine or dexamfetamine should
be used
9 n/aa ✓
16 Reasons to choose atomoxetine should include unresponsive to
methylphenidate or intolerable adverse effects
9 n/aa ✓
13 Clinicians should check and document whether or not the child
can swallow pills
7 7.3 ✓
48 Stimulant drugs should be titrated with regular step-wise dose
increases to achieve the minimum effect dose
9 9 ✓
56 The titration schedule should be documented at initiation
specifying drug, dose, duration of each step and review date
9 9 ✓
15 Methylphenidate should normally be considered the first-line drug
for treatment of ADHD
9 n/aa ✓
25 Before initiation of medication, different drug options in terms of
benefits (e.g. different duration of action) and adverse effects
should be discussed with parents and children (age >11)
9 9 ✓
28 Drug information sheets should include details of what parents
should do if adverse effects occur
9 9 ✓
29 A medication protocol should include drug information sheets 9 8.5 ✓
61 The duration of the dose titration phase should be a maximum of
12 weeks (2–4 weeks between dose increments)
8 8 ✓
84 After the first 6 months (of medication maintenance) clinic follow-
up should be every 6 months
8 9 ✓
24 A medication protocol should include a prescribing algorithm/flow
chart
8 n/aa ✓
59 During titration the dose should be increased as required up to
BNF limits
8 8 ✓
32 Before initiation of medication, parents and young people should
be asked to list separately the 3 most desired outcomes of
treatment
8 8 ✓
Reasons to choose atomoxetine should include:
17 Parent/child preference 7 n/aa ✓
18 History/risk of drug diversion 7 n/aa ✓
19 History/risk of substance misuse 7 n/aa ✓
ADHD, attention-deficit hyperactivity disorder; BNF, British National Formulary; MTA, Multimodal Treatment of ADHD; n/a, not applicable; NICE, National Institute for Health and Care
Excellence; Texas, Texas Children's Medication Algorithm Project.
a. Additional statements (n=7) rated on importance only.
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feasible during titration. Consensus emerged on the importance of
monthly clinic contact and weekly telephone/email contact with the
family during titration and these schedules of contact were
perceived as beneficial by 91% (20/22) and 82% (18/22) of online
survey respondents respectively. However, there was no agreement
on the feasibility of this approach (Table 2, statements 52 and 54).
Assessing response to medication: use of rating scales
and assessment of side-effects
Support for the importance and feasibility of the NICE recom-
mendation for parents to record side-effects at each dose change
emerged from the Delphi study (Table 1, statement 62). However,
27% (6/22) of respondents from the online survey indicated that
they did not use side-effect rating scales. Healthcare professionals
commented at the workshop that assessment of side-effects was
primarily achieved by monitoring physical health and via clinical
enquiry; a lack of easily available and validated side-effect scales
may be a barrier to their use.
Clinicians reached a consensus on the importance of the
administration of the Conners’ short form (26 item) question-
naire26 with parents, teachers and the young person at baseline
(Table 2, statements 34, 37 and 40). However, variation among
healthcare professionals in the range and number of rating scales
used in the UK has been previously reported27 and clinical enquiry
may be a preferred source of information: all online survey
respondents (22/22) placed value on the parents’ view, the child’s
view and the parents’ perception of progress at school when
determining response to medication.
Medication maintenance: frequency of clinic contact
NICE recommendations for annual reviews of medication, assess-
ment of concordance with medication via discussion with parents
Table 2 Category 2 Delphi statements (n=19): rated as ‘ important’ but ‘not feasible’
Delphi
statement
number Category 2 statements
Importance
median
score
Feasibility
median
score
Source:
NICE
Source:
MTA/
Texas
Source:
stakeholder
Source:
study
team
7 Drug treatment should only be offered to children together with
behavioural management advice
8.5 6.5 ✓
9 Children with mild/moderate ADHD should be offered behaviour
therapy/parent training before a trial of medication is
considered
7.5 5 ✓
54 Monitoring of improvement/adverse-effects using telephone/SMS
or email contact with the parent/young person should occur
weekly during the titration phase
7.5 4.5 ✓ ✓
83 During the first 6 months (of medication maintenance) clinic
follow-up should be every 3 months
8.5 8 ✓
98 Heart rate and blood pressure should be monitored after each
dose change
9 9 ✓
100 Heart rate and blood pressure should be recorded on a centile
chart
8.5 6 ✓
26 Information sheets describing all available potential ADHD
medications should be routinely provided to parents, young
people (>11) and teachers
8.5 6.5 ✓
27 An information sheet on the medication to be prescribed should
be routinely provided to parents, young people (>11), GPs and
teachers
9 7.8 ✓
30 A designated individual (teacher/SENCO) within a school should
be identified to provide feedback and liaison
8 6 ✓
31 For children in secondary school, more than one teacher’s view
should be acquired
7.8 5 ✓
42 A side-effect rating scale should be completed before initiation of
medication
7.3 6 ✓
52 During titration, the child should be seen in clinic on a monthly
basis
8 7 ✓
10 All pre-school children with ADHD should be offered behaviour
therapy/parent training before a trial of medication is
considered
9 4 ✓
12 In children with comorbid ODD/CD or mood disorders, ADHD
medication should be used together with psychological
interventions
8 7 ✓
34 The Conners short form (26 item) should be completed by parents
at baseline (pre-medication)
9 8 ✓
37 The Conners short form (26 item) should be completed by
teachers at baseline (pre-medication)
8.5 5.5 ✓
40 The Conners short form (26 item) self-report should be completed
by young people (>11 years) at baseline (pre-medication)
7 5 ✓
73 At the end of the titration phase the side-effect scale should be
repeated by parents
7 6 ✓
76 At the end of the titration phase the Conners short form (26 item)
should be repeated by TEACHERS
7 3 ✓
ADHD, attention-deficit hyperactivity disorder; CD, conduct disorder; GP, general practitioner; MTA, Multimodal Treatment of ADHD; NICE, National Institute for Health and Care
Excellence; ODD, oppositional defiant disorder; SENCO, special educational needs coordinator; Texas, Texas Children's Medication Algorithm Project.
The statements are based on information from their ascribed source; they have not been taken verbatim from each source.
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and patient, and monitoring of height and weight at fixed intervals
after starting medication all reached consensus for both impor-
tance and feasibility in the Delphi study (Table 1, statements 101,
86, 95 and 96). Delphi study findings indicate consensus on the
importance and feasibility of clinic follow-ups every 6 months,
after the first 6 months of treatment (Table 1, statement 84). This
aligns with results from the online survey, whereby biannual
contact during maintenance was rated as beneficial and feasible by
77% (17) and 95% (21) of respondents respectively.
Delphi study responses met consensus on the importance of
monitoring blood pressure and pulse after every dose change
(Table 2, statement 98) and although the median score was high
(9, very important) there was no consensus on the feasibility of
this NICE recommendation, which healthcare professionals
acknowledged as problematic to achieve in practice. This high-
lights an implementation challenge regarding obtaining recordings
between clinic visits. This may be an area where home or
ambulatory recordings sent electronically to the clinic using a
telemedicine approach may help to bridge this implementa-
tion gap.
The greater frequency of contact observed in the MTA’s
medication management arm provided opportunity to identify
and immediately adjust changes in medication needs during
maintenance, indicating a need for long-term close monitoring.28
Additional forms of communication (email, SMS, smart telephone
apps) could help to ensure adequate assessment of medication
response if intensive face-to-face clinic monitoring is not feasible
and may help to maintain the lines of communication desired by
parents/carers.
Acquisition of feedback from school and importance of
school input
The Delphi study revealed consensus for both the importance of
having a nominated individual teacher to provide feedback and in
the case of secondary school-age children, gathering information
from more than one teacher (Table 2, statements 30 and 31).
However, there was no consensus on the feasibility of this.
Healthcare professionals from the workshop highlighted difficul-
ties in getting school information, citing it was ‘time-consuming’.
Obtaining teacher feedback relating to a child’s response to
treatment has been deemed ‘critical’29 and is a NICE recommen-
dation. However, our findings support previous research indicat-
ing that resource limitations are a barrier to guideline
implementation.30
Discussion
Summary of main findings
Half (50%) of the NICE ADHD guideline recommendations
included in the Delphi study were endorsed as being both
clinically important and feasible to implement. These included
assessment of ADHD-related impairment, baseline physical exam-
ination, recording of height, weight and parental reported side-
effects, communicating reasons to use atomoxetine and methyl-
phenidate (see Table 1 for complete list). Meanwhile, a subset of
NICE recommendations, although regarded as clinically impor-
tant, was identified as difficult or challenging to implement in
routine UK clinical practice. These included delivery of adjunctive
behavioural interventions, weekly monitoring (telephone/SMS/
email) during titration, measuring pulse and blood pressure after
every dose change during titration and recording pulse and blood
pressure on a centile chart (see Table 2 for complete list).
Study strengths, limitations and future research
To the best of our knowledge, this is the first study which has
explicitly sought to understand current consensus on medication
management strategies for ADHD within the constraints of real-
world practice. Whereas the number of Delphi panelists (n=12)
may be considered relatively small, this is sufficient to demon-
strate consensus. There is no consensus in the literature on
optimum sample size31 and panel sizes ranging from 10 to 1142
participants are apparent in published Delphi studies.32 However,
Jones & Hunter19 recommend a Delphi panel size of between 9
and 12 participants. Although the sample size of the online survey,
workshop and focus groups were also small, the combination of
opinion of multiple stakeholders to inform the items of the Delphi
survey enabled a more complete approach to understanding issues
pertinent to clinicians, young people, parent and carers in relation
to ADHD medication management. Given that the participant is
often over-looked in determining ‘best practice’, our inclusion of
this group is a real strength.
This study only elicited the views of participants located
within the East Midlands region of England; thus, it is possible
that healthcare professionals working in different healthcare
systems may make different judgements about the importance
and feasibility of ADHD practice recommendations. Furthermore,
the characteristics of the patients being treated by the healthcare
professionals completing the Delphi study were not determined: it
is likely that these too will have influenced judgements about what
is important and feasible. Additionally, the use of self-report to
determine current practices may have been subject to biases such
as overestimation of adherence to guidelines33 and triangulation
with other objective assessments of patient management (e.g.
case-note audits) would be a further method to characterise
current practice.
Given the lack of understanding of current consensus in
medication management in the UK, it was important to first
establish current opinion on what constitutes ‘best practice’
within the constraints of everyday practice. Further research
should establish the extent to which protocols are adhered to
and factors that influence non-adherence by combining audit data
with survey responses or qualitative interviews. Given the
importance of regular contact during titration, future research
could investigate whether utilisation of technology, such as Skype
or apps, could provide a satisfactory interface for such monitoring.
Although not specific to ADHD medication monitoring, a recent
study did explore service user opinion of routine monitoring via
an electronic questionnaire in mental health settings.30 The
findings revealed that parents and children were supportive of
the use of technology to report progress to their healthcare
professional.
Our study applied an iterative, mixed methods approach
(literature review, online survey, stakeholder workshop and Delphi
study) to determine previously unexplored perceptions of the
implementation of national clinical guidelines and evidence-based
recommendations for children and young people receiving
medication for ADHD. Our findings indicate areas of agreement
and discord with existing NICE3 ADHD guidelines and conflict
between the perceived importance of some best practice medica-
tion management strategies and the feasibility of their implemen-
tation. The study has identified a set of ADHD practice
recommendations that are viewed by clinicians as important but
currently not feasible to implement. These recommendations
should be the focus of health service implementation strategies
and research.
Clinician feedback indicated that the intensive monitoring
schedules of the MTA protocol are currently regarded as
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impractical in routine UK practice and the time needed to titrate
medication is likely to extend beyond that recommended by NICE
guidelines. The use of technology to automate data collection and
provide digital communication may be particularly relevant for
aspects of practice viewed as important but currently unfeasible.
The Delphi study findings have identified recommendations for
practice where implementation challenges remain and clinical
consensus is still to be reached. These findings could inform the
update of the NICE ADHD clinical guideline and focus imple-
mentation strategies on those statements identified as important
but not presently feasible to deliver in routine care. One potential
area for development is the application of digital technologies to
assist remote monitoring and follow-up during medication titra-
tion and optimisation.
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